Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
D. Araújo Barros Coelho (Porto, Portugal), C. Sousa (Porto, Portugal), M. Jacob (Porto, Portugal), L. Almeida (Porto, Portugal), D. Araújo (Porto, Portugal), H. Novais-Bastos (Porto, Portugal), A. Magalhães (Porto, Portugal), C. Souto Moura (Porto, Portugal), L. Cirnes (Porto, Portugal), V. Hespanhol (Porto, Portugal), H. Queiroga (Porto, Portugal), G. Fernandes (Porto, Portugal). Progression after osimertinib in EGFR T790M-mutated non-small cell cancer patients. 1694

Member's Comments

No comment yet.

Related content which might interest you: Management of EGFR mutated nonsmall cell lung carcinoma patients Source: Eur Respir J 2015; 45: 1132-1141 Year: 2015 Advanced non-small cell lung cancer in elderly patients Source: Breathe 2012; 9: 26-34 Year: 2012 Prognostic  value of  EGFR  genotype  in  EGFR-mutant  non-small  cell lung  cancer Source: International Congress 2018 – Lung cancer: from the bench to the bedside Year: 2018 Characterization of patients with non-small cell lung cancer (NSCLC) relative to its EGFR mutational status Source: Annual Congress 2011 - Epidemiology of lung cancer and screening Year: 2011 Anticancer treatment for advanced non-small cell lung cancer Source: Breathe 2011; 8: 124-133 Year: 2011 Our experience with crizotinib in the treatment of non-small cell lung cancer Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer Year: 2020 How to treat brain metastasis in patients with non-small cell lung carcinoma (NSCLC) and EGFR mutations Source: International Congress 2015 – How to treat brain metastases Year: 2015 Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients Source: ERJ Open Res, 4 (1) 00058-2017; 10.1183/23120541.00058-2017 Year: 2018 Targeted therapy in non-small cell lung cancer Source: Breathe 2012; 8: 206-215 Year: 2012 Expression of Her-2/neu and Bcl-2 in patients with non-small cell lung cancer Source: International Congress 2017 – Gene signatures in bronchial diseases Year: 2017 The efficacy of Ado-trastuzumab emtansine in HER-2 aberrant non-small cell lung cancer Source: International Congress 2019 – Thoracic oncology: Treatment, diagnostic options and biology Year: 2019 p-53 and HER2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer Source: Annual Congress 2007 - Novel genetic markers in pathology Year: 2007 K-RAS oncogenic mutations in patients with nonsmall cell lung cancer Source: Annual Congress 2007 - Biology of thoracic malignancies Year: 2007 Enhanced FGFR signaling correlates with erlotinib/bevacizumab response in advanced non-squamous non-small cell lung cancer Source: International Congress 2015 – Advances in the therapy of lung cancer Year: 2015 Evaluate soluble PD-L1 in plasma in advanced stage non-small cell lung cancer patients Source: Virtual Congress 2020 – Biological mechanisms of lung cancer Year: 2020 Ki-67 in non-small cell lung cancer Source: Annual Congress 2012 - New results in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease Year: 2012 Therapeutic management of ALK+ nonsmall cell lung cancer patients Source: Eur Respir J 2015; 46: 230-242 Year: 2015 Second line therapy for advanced non-small cell lung cancer Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 Radio(chemo)therapy in locally advanced nonsmall cell lung cancer Source: Eur Respir Rev 2015; 25: 65-70 Year: 2016 Prognostic factors affecting survival in advanced non-small cell lung cancer patients Source: Eur Respir J 2004; 24: Suppl. 48, 75s Year: 2004